Design of the Largest Clinical Trial of Oxytocin for Autism Social Behavior

SOARS-B is the most well-powered clinical trial to date testing whether intranasal oxytocin can improve social behaviors in children with autism spectrum disorder.

Spanos, Marina et al.·Contemporary clinical trials·2020·not yet reportedclinical trial design
RPEP-05147Clinical trial designnot yet reported2020RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical trial design
Evidence
not yet reported
Sample
N=large
Participants
290 children and teens ages 3-17 with ASD across 7 US sites

What This Study Found

SOARS-B enrolled 290 participants across seven sites for a 24-week randomized trial of intranasal oxytocin in ASD, making it the best-powered study to date.

Key Numbers

n=290; ages 3-17; 7 sites; 24 weeks double-blind + 24 weeks open-label; plasma oxytocin and OXTR methylation measured

How They Did This

Phase 2 randomized, placebo-controlled, multi-site clinical trial with 24 weeks blinded treatment, 24 weeks open-label extension, and biomarker measurements.

Why This Research Matters

Previous small oxytocin-autism studies produced conflicting results. This large trial aims to definitively determine whether intranasal oxytocin improves social behaviors in children with ASD.

The Bigger Picture

This trial represents the most rigorous test of the oxytocin hypothesis for autism treatment, promising to either validate a new approach or redirect research efforts.

What This Study Doesn't Tell Us

Design paper only — no results reported. Trial outcomes are not yet available in this publication.

Questions This Raises

  • ?Will intranasal oxytocin produce clinically meaningful improvements in social behavior?
  • ?Which biomarkers predict oxytocin treatment response in ASD?
  • ?Are effects sustained after treatment discontinuation?

Trust & Context

Key Stat:
290 children Enrolled in the most well-powered trial of intranasal oxytocin for autism to date
Evidence Grade:
Trial design paper describing methodology only, with no efficacy results. The design is rigorous (randomized, placebo-controlled, multi-site).
Study Age:
Published in 2020 as a design paper. Results from SOARS-B have since been published.
Original Title:
Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).
Published In:
Contemporary clinical trials, 98, 106103 (2020)
Database ID:
RPEP-05147

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why is oxytocin being tested for autism?

Oxytocin is a neuropeptide involved in social bonding and trust. Research suggests it may enhance social attention and reward in people with autism, potentially improving social interaction. However, previous small studies had mixed results.

What makes this trial different from earlier studies?

SOARS-B is much larger (290 children vs. dozens in prior studies), longer (48 weeks total), and conducted across 7 sites, giving it statistical power to detect effects that smaller studies could not.

Read More on RethinkPeptides

Cite This Study

RPEP-05147·https://rethinkpeptides.com/research/RPEP-05147

APA

Spanos, Marina; Chandrasekhar, Tara; Kim, Soo-Jeong; Hamer, Robert M; King, Bryan H; McDougle, Christopher J; Sanders, Kevin B; Gregory, Simon G; Kolevzon, Alexander; Veenstra-VanderWeele, Jeremy; Sikich, Linmarie. (2020). Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).. Contemporary clinical trials, 98, 106103. https://doi.org/10.1016/j.cct.2020.106103

MLA

Spanos, Marina, et al. "Rationale, design, and methods of the Autism Centers of Excellence (ACE) network Study of Oxytocin in Autism to improve Reciprocal Social Behaviors (SOARS-B).." Contemporary clinical trials, 2020. https://doi.org/10.1016/j.cct.2020.106103

RethinkPeptides

RethinkPeptides Research Database. "Rationale, design, and methods of the Autism Centers of Exce..." RPEP-05147. Retrieved from https://rethinkpeptides.com/research/spanos-2020-rationale-design-and-methods

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.